MUMBAI: Anti-diabetic drug has been launched by Zydus Cadila at an aggressive price of Rs. 7 per day, it is almost 1/6th the price of gliptins which is established by MNCs.
The company added that the main aim of their intentions was to provide ‘breakthrough’ drug, Tenglyn to the diabetic patients’ affordable pricing.
The domestic companies such as Glenmark Pharma and Ajanta which are selling this drug charged one-third of the price on this it. Experts are though that when the completion will come between companies the price of this drug can be decreased but now the all companies are watching as well as waiting the development of it.
The teneligliptin, a third generation new oral anti-drug was first started by Glenmark in the month of June and charge for it approximately Rs. 20 for a day’s therapy. Now, this is being priced nearly Rs. 45 for a day’s therapy against for previous price, yearly the cost of it is Rs. 16, 500. Zydus added that who prescribed gliptin which was launched by them saving more amounts.
Generally, the oral anti-diabetic market, the teneligliptin is valued approximately Rs. 5,000 crore and it will be increasing at 20% per annum. The gliptin family price is at Rs. 1, 200 crores and it will be increased at 25%.